These receptors were also shown to be upregulated in patients with AATD following double-dose augmentation treatment with purified AAT compared with a single dose, suggesting that a similar mechanism to enhance efferocytosis may existin vivo. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.